Patents by Inventor John Philip Mayer

John Philip Mayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides and methods for their preparation and use
    Patent number: 8815811
    Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: August 26, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Krister Bengt Bokvist, Lili Guo, John Philip Mayer
  • GLP-1 pegylated compounds
    Patent number: 8183340
    Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 22, 2012
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, Jr., Andrew Mark Vick, Lianshan Zhang
  • NOVEL PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE
    Publication number: 20110237503
    Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 29, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jorge ALSINA-FERNANDEZ, Krister Bengt BOKVIST, Lili GUO, John Philip MAYER
  • Glp-1 Pegylated Compounds
    Publication number: 20090215981
    Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.
    Type: Application
    Filed: May 11, 2006
    Publication date: August 27, 2009
    Inventors: Wolfgang Glaesner, John Philip Mayer, Rohn Lee Millican, JR., Andrew Mark Vick, Lianshan Zhang
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20090118167
    Abstract: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.
    Type: Application
    Filed: August 11, 2005
    Publication date: May 7, 2009
    Applicant: Eli Lilly and Company Patent Division
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080146500
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: June 19, 2008
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20080096811
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: May 19, 2005
    Publication date: April 24, 2008
    Applicant: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Jesper Lindgren Gromada, Robert Chadwick Cummins, Wolfgang Glaesner, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez
  • Melanocortin receptor agonists
    Patent number: 7291619
    Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: November 6, 2007
    Assignee: Eli Lilly and Company
    Inventors: Christopher Kelly Biggers, Karin Briner, Christopher William Doecke, Matthew Joseph Fisher, Larry Wayne Hertel, Vincent Mancuso, Michael John Martinelli, John Philip Mayer, Paul Leslie Ornstein, Timothy Ivo Richardson, Jikesh Arvind Shah, Qing Shi, Zhipei Wu, Chaoyu Xie
  • Melanocortin receptor agonists
    Publication number: 20040092507
    Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.
    Type: Application
    Filed: July 11, 2003
    Publication date: May 13, 2004
    Inventors: Christopher Kelly Biggers, Karin Briner, Christopher William Doecke, Matthew Joseph Fisher, Larry Wayne Hertel, Vincent Mancuso, Michael John Martinelli, John Philip Mayer, Paul Leslie Ornstein, Timothy Ivo Richardson, Jikesh Arvind Shah, Qing Shi, Zhipei Wu, Chaoyu Xie
  • Use of trichloroacetimidate linker for peptide synthesis
    Publication number: 20040039161
    Abstract: The present invention provides a solid phase peptide synthetic method for the preparation of C-terminal alchohols, wherein the improvement consists of using trichloroacetimidate as the linker.
    Type: Application
    Filed: August 22, 2002
    Publication date: February 26, 2004
    Inventors: John Philip Mayer, Liang Zeng Yan
  • Method for treating Schwann and colon cells in vitro
    Patent number: 5929032
    Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Method for the treatment of Schwann cells in vivo
    Patent number: 5849705
    Abstract: Schwann cells can be treated in vivo to survive longer and to proliferate by contacting them with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer
  • Method for the treatment of colon epithelial cells in vivo
    Patent number: 5686415
    Abstract: Colon epithelial cells are stimulated to multiply, grow and mature by contacting them in vivo with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: November 11, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • NDF peptides
    Patent number: 5670342
    Abstract: Novel peptides are described which are biologically active derivatives of the EGF-like domain of NDF/heregulins and which stimulate the proliferation and differentiation of colon epithelial cells and support the survival and growth of Schwann cells.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 23, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga